KRAS and non-small cell lung carcinoma: Structurally targeted chemical modifications of sotorasib allowed for the synthesis of adagrasib (MRTX849), a highly selective covalent inhibitor of mutated KRAS G12C, which, in December 2022, received accelerated approval by FDA (Krazati®, Mirati Pharmaceutics) for the treatment of patients with KRAS G12C–mutated metastatic or unresectable NSCLC (NCT03785249 KRISTAL-1) [41].